Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
88.26 (1y: +107%)
Market Cap 6.52 B P/E(ttm) 1961.40
Enterprise Value 5.88 B P/B 47.20
PCYC- NAS (USA)
Pharmacyclics, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$88.26
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry		 vs
history
Cash to Debt No Debt
PCYC's Cash to Debt is ranked higher than
83% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. PCYC: No Debt )
PCYC' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: No Debt
Equity to Asset 0.603
PCYC's Equity to Asset is ranked higher than
64% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. PCYC: 0.603 )
PCYC' s 10-Year Equity to Asset Range
Min: -0.49   Max: 0.98
Current: 0.6
-0.49
0.98
Interest Coverage No Debt
PCYC's Interest Coverage is ranked higher than
99% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.70 vs. PCYC: No Debt )
PCYC' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 1
Z-Score: 36.82
M-Score: -2.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating margin (%) 14.50
PCYC's Operating margin (%) is ranked higher than
81% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.80 vs. PCYC: 14.50 )
PCYC' s 10-Year Operating margin (%) Range
Min: -24376.8   Max: 14.5
Current: 14.5
-24376.8
14.5
Net-margin (%) 14.6
PCYC's Net-margin (%) is ranked higher than
85% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. PCYC: 14.6 )
PCYC' s 10-Year Net-margin (%) Range
Min: -23291.7   Max: 14.6
Current: 14.6
-23291.7
14.6
ROE (%) 9.1
PCYC's ROE (%) is ranked higher than
79% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. PCYC: 9.1 )
PCYC' s 10-Year ROE (%) Range
Min: -107.2   Max: 9.1
Current: 9.1
-107.2
9.1
ROA (%) 5.5
PCYC's ROA (%) is ranked higher than
76% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. PCYC: 5.5 )
PCYC' s 10-Year ROA (%) Range
Min: -300   Max: 5.5
Current: 5.5
-300
5.5
Revenue Growth (%) 226
PCYC's Revenue Growth (%) is ranked higher than
100% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. PCYC: 226 )
PCYC' s 10-Year Revenue Growth (%) Range
Min: -50   Max: 226
Current: 226
-50
226
ยป PCYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

PCYC Guru Trades in Q2 2012

Louis Moore Bacon Sold Out
Jeremy Grantham Sold Out
George Soros Sold Out
PRIMECAP Management 3,173,739 sh (-19.35%)
Steven Cohen 14,817 sh (-31.36%)
» More
Q3 2012

PCYC Guru Trades in Q3 2012

Paul Tudor Jones 7,900 sh (New)
Jeremy Grantham 4,600 sh (New)
Jim Simons 145,000 sh (New)
Steven Cohen 123,403 sh (+732.85%)
PRIMECAP Management 3,004,439 sh (-5.33%)
» More
Q4 2012

PCYC Guru Trades in Q4 2012

Joel Greenblatt 41,832 sh (New)
Steven Cohen 397,898 sh (+222.44%)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
PRIMECAP Management 2,895,339 sh (-3.63%)
» More
Q1 2013

PCYC Guru Trades in Q1 2013

Jim Simons 9,500 sh (New)
Steven Cohen 580,251 sh (+45.83%)
Joel Greenblatt Sold Out
PRIMECAP Management 2,440,239 sh (-15.72%)
» More
» Details

Insider Trades

Latest Guru Trades with PCYC

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Sold Out 0.14%$57.78 - $94.2 $ 88.2614%0
Joel Greenblatt 2012-12-31 New Buy0.14%$47.87 - $69.78 $ 88.2650%41832
George Soros 2012-06-30 Sold Out 0.04%$25.72 - $53.44 $ 88.26171%0
George Soros 2012-03-31 New Buy0.04%$14.99 - $28.68 $ 88.26322%100000
PRIMECAP Management 2011-06-30 Add 21.34%0.01%$5.66 - $10.63 $ 88.261131%4011958
PRIMECAP Management 2010-06-30 Add 43.36%0.01%$5.53 - $8.18 $ 88.261164%3306481
Premium More recent guru trades are included for Premium Members only!!
ยป Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/E(ttm) 1961.40
PCYC's P/E(ttm) is ranked lower than
70% of the 497 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.30 vs. PCYC: 1961.40 )
PCYC' s 10-Year P/E(ttm) Range
Min: 35.9   Max: 2050
Current: 1961.4
35.9
2050
P/B 47.20
PCYC's P/B is ranked lower than
69% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. PCYC: 47.20 )
PCYC' s 10-Year P/B Range
Min: 0.26   Max: 47.2
Current: 47.2
0.26
47.2
P/S 35.50
PCYC's P/S is ranked lower than
68% of the 654 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. PCYC: 35.50 )
PCYC' s 10-Year P/S Range
Min: 10.87   Max: 1254.17
Current: 35.5
10.87
1254.17
PFCF 114.00
PCYC's PFCF is ranked lower than
53% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.96 vs. PCYC: 114.00 )
PCYC' s 10-Year PFCF Range
Min: 8.05   Max: 114
Current: 114
8.05
114
EV-to-EBIT 1000
PCYC's EV-to-EBIT is ranked lower than
69% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.43 vs. PCYC: 1000 )
PCYC' s 10-Year EV-to-EBIT Range
Min: 24   Max: 400.3
Current: 1000
24
400.3

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 53.2
PCYC's Price/Net Cash is ranked lower than
65% of the 184 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. PCYC: 53.2 )
PCYC' s 10-Year Price/Net Cash Range
Min: 1.8   Max: 33.9
Current: 53.2
1.8
33.9
Price/Net Current Asset Value 1103.3
PCYC's Price/Net Current Asset Value is ranked lower than
68% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.20 vs. PCYC: 1103.3 )
PCYC' s 10-Year Price/Net Current Asset Value Range
Min: 42.9   Max: 682.6
Current: 1103.3
42.9
682.6
Price/Tangible Book 47.2
PCYC's Price/Tangible Book is ranked lower than
71% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. PCYC: 47.2 )
PCYC' s 10-Year Price/Tangible Book Range
Min: 1.7   Max: 30
Current: 47.2
1.7
30
Price/DCF (Projected) 19.8
PCYC's Price/DCF (Projected) is ranked lower than
64% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. PCYC: 19.8 )
PCYC' s 10-Year Price/DCF (Projected) Range
Min: 72.8   Max: 72.8
Current: 19.8
Price/Median PS Value 1
PCYC's Price/Median PS Value is ranked higher than
59% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. PCYC: 1 )
PCYC' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 9.5
Current: 1
0.6
9.5
Price/Graham Number 33.9
PCYC's Price/Graham Number is ranked lower than
72% of the 422 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.00 vs. PCYC: 33.9 )
PCYC' s 10-Year Price/Graham Number Range
Min: 21   Max: 21
Current: 33.9
Earnings Yield (Greenblatt) 0.10
PCYC's Earnings Yield (Greenblatt) is ranked lower than
52% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. PCYC: 0.10 )
PCYC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 4.2
Current: 0.1
0.1
4.2
Forward Rate of Return (Yacktman) -0.62
PCYC's Forward Rate of Return (Yacktman) is ranked lower than
53% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. PCYC: -0.62 )
PCYC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.9   Max: -0.7
Current: -0.62
-9.9
-0.7

Business Description

Pharmacyclics, Inc. was incorporated in Delaware in 1991 and commenced operations in 1992. Pharmacyclics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's corporate mission statement reads as follows: To build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious medical healthcare needs; To identify promising product candidates based on exceptional scientific development expertise, develop its products in a rapid, cost-efficient manner and to pursue commercialization and/or development partners when and where appropriate. It exists to make a difference for the better and these are important times to do that. Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs toward potential commercialization. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It currently has three proprietary drug candidates under clinical development and several preclinical lead molecules. These include: an inhibitor of Bruton's tyrosine kinase (BTK) ibrutinib (PCI-32765, hereafter referred to as ibrutinib) currently initiating Phase III studies in hematologic malignancies, a BTK inhibitor lead optimization program targeting anti-inflammatory and autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer and a HDAC inhibitor abexinostat (formerly known as PCI-24781) currently in Phase I and II clinical trials in solid tumors and hematological malignancies.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:PY2.Germany
ยป More Articles for PCYC

Headlines

Articles On GuruFocus.com
comment on PCYC Mar 06 2013 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 
Pharmacyclics Inc. Reports Operating Results (10-Q) Feb 08 2011 
Pharmacyclics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Weekly CEO Buys Highlight: Pharmacyclics Inc, Saul Centers Inc, Charming Shoppes Inc, ProLogis, Exce Jun 27 2010 
Pharmacyclics Inc. Reports Operating Results (10-Q) May 07 2010 
cooldecency99 note on PCYC May 01 2010 
cooldecency99 note on PCYC May 01 2010 
Pharmacyclics Inc. Reports Operating Results (10-Q) Nov 03 2009 
Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results Feb 13 2009 

More From Our Partners
Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB) Jun 12 2013 - BENZINGA

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK